Search Results - "Schumacher, Ton"

Regulation and Function of the PD-L1 Checkpoint by Sun, Chong, Mezzadra, Riccardo, Schumacher, Ton N.

“…Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits…”
Get full text

Tertiary lymphoid structures in cancer by Schumacher, Ton N, Thommen, Daniela S

“…Ectopic lymphoid aggregates, termed tertiary lymphoid structures (TLSs), are formed in numerous cancer types, and, with few exceptions, their presence is…”
Get full text

Cancer Neoantigens by Schumacher, Ton N, Scheper, Wouter, Kvistborg, Pia

“…Malignant transformation of cells depends on accumulation of DNA damage. Over the past years we have learned that the T cell-based immune system frequently…”
Get full text

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma by Zaretsky, Jesse M, Garcia-Diaz, Angel, Shin, Daniel S, Escuin-Ordinas, Helena, Hugo, Willy, Hu-Lieskovan, Siwen, Torrejon, Davis Y, Abril-Rodriguez, Gabriel, Sandoval, Salemiz, Barthly, Lucas, Saco, Justin, Homet Moreno, Blanca, Mezzadra, Riccardo, Chmielowski, Bartosz, Ruchalski, Kathleen, Shintaku, I. Peter, Sanchez, Phillip J, Puig-Saus, Cristina, Cherry, Grace, Seja, Elizabeth, Kong, Xiangju, Pang, Jia, Berent-Maoz, Beata, Comin-Anduix, Begoña, Graeber, Thomas G, Tumeh, Paul C, Schumacher, Ton N.M, Lo, Roger S, Ribas, Antoni

“…Whole-exome sequencing was performed on four patients' tumors before exposure to pembrolizumab and after disease progression following a response to treatment…”
Get full text

Neoantigens in cancer immunotherapy by Schumacher, Ton N., Schreiber, Robert D.

“…The clinical relevance of T cells in the control of a diverse set of human cancers is now beyond doubt. However, the nature of the antigens that allow the…”
Get full text

T Cell Dysfunction in Cancer by Thommen, Daniela S., Schumacher, Ton N.

“…Therapeutic reinvigoration of tumor-specific T cells has greatly improved clinical outcome in cancer. Nevertheless, many patients still do not achieve durable…”
Get full text

T Cell Fate at the Single-Cell Level by Buchholz, Veit R, Schumacher, Ton N.M, Busch, Dirk H

“…T cell responses display two key characteristics. First, a small population of epitope-specific naive T cells expands by several orders of magnitude. Second,…”
Get full text

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators by Mezzadra, Riccardo, Sun, Chong, Jae, Lucas T., Gomez-Eerland, Raquel, de Vries, Evert, Wu, Wei, Logtenberg, Meike E. W., Slagter, Maarten, Rozeman, Elisa A., Hofland, Ingrid, Broeks, Annegien, Horlings, Hugo M., Wessels, Lodewyk F. A., Blank, Christian U., Xiao, Yanling, Heck, Albert J. R., Borst, Jannie, Brummelkamp, Thijn R., Schumacher, Ton N. M.

“…CMTM6 and CMTM4 bind to and stabilize the inhibitory receptor PD-L1 and regulate PD-L1 levels at the surface of human tumour and immune cells. Regulating…”
Get full text

The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues by Kok, Lianne, Masopust, David, Schumacher, Ton N.

“…CD8 + tissue resident memory T cells (T RM cells) are essential for immune defence against pathogens and malignancies, and the molecular processes that lead to…”
Get full text

The cancer antigenome by Heemskerk, Bianca, Kvistborg, Pia, Schumacher, Ton N M

“…Cancer cells deviate from normal body cells in two immunologically important ways. First, tumour cells carry tens to hundreds of protein‐changing mutations…”
Get full text

CD8+ T cell states in human cancer: insights from single-cell analysis by van der Leun, Anne M., Thommen, Daniela S., Schumacher, Ton N.

“…The T cell infiltrates that are formed in human cancers are a modifier of natural disease progression and also determine the probability of clinical response…”
Get full text

The CD47-SIRPα Immune Checkpoint by Logtenberg, Meike E.W., Scheeren, Ferenc A., Schumacher, Ton N.

“…The cytotoxic activity of myeloid cells is regulated by a balance of signals that are transmitted through inhibitory and activating receptors. The Cluster of…”
Get full text

The "cancer immunogram" by Blank, Christian U., Haanen, John B., Ribas, Antoni, Schumacher, Ton N.

“…Visualizing the state of cancer–immune system interactions may spur personalized therapy The impact of cancer immunotherapy on clinical cancer care is growing…”
Get full text

Safety switches for adoptive cell therapy by Sahillioglu, Ali Can, Schumacher, Ton N

“…•Synthetic biology tools enable reversible and dose dependent control of cell products.•Drug responsive switches modulate endogenous and transduced antigen…”
Get full text

Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy by Kelderman, Sander, Schumacher, Ton N., Kvistborg, Pia

“…Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly…”
Get full text

Neoantigens encoded in the cancer genome by Schumacher, Ton N, Hacohen, Nir

“…Highlights • DNA damage and neoantigen formation correlate with local immune activity and outcome. • Intratumoral heterogeneity affects response to…”
Get full text

Adoptive cellular therapy: a race to the finish line by June, Carl H, Riddell, Stanley R, Schumacher, Ton N

“…Adoptive T cell transfer for cancer, chronic infection, and autoimmunity is an emerging field that shows promise in recent trials. Using the principles of…”
Get more information

Biomarkers in Cancer Immunotherapy by Schumacher, Ton N., Kesmir, Can, van Buuren, Marit M.

“…Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these…”
Get full text

Diverse and heritable lineage imprinting of early haematopoietic progenitors by Naik, Shalin H., Perié, Leïla, Swart, Erwin, Gerlach, Carmen, van Rooij, Nienke, de Boer, Rob J., Schumacher, Ton N.

“…In vivo ‘cellular barcoding’ shows that early haematopoietic progenitors are heterogeneous in the cell types that they produce, and this is partly due to an…”
Get full text

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma by Kelderman, Sander, Heemskerk, Bianca, van Tinteren, Harm, van den Brom, Rob R. H., Hospers, Geke A. P., van den Eertwegh, Alfonsus J. M., Kapiteijn, Ellen W., de Groot, Jan Willem B., Soetekouw, Patricia, Jansen, Rob L., Fiets, Edward, Furness, Andrew J. S., Renn, Alexandra, Krzystanek, Marcin, Szallasi, Zoltan, Lorigan, Paul, Gore, Martin E., Schumacher, Ton N. M., Haanen, John B. A. G., Larkin, James M. G., Blank, Christian U.

“…Introduction Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved overall survival (OS) in metastatic melanoma in phase…”
Get full text